カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界の慢性閉塞性肺疾患（COPD）治療薬市場2022年-2031年：薬物クラス別（併用療法、気管支拡張薬、副腎皮質ステロイド、ホスホジエステラーゼ4型阻害剤、去痰薬、その他）

◆英語タイトル：Chronic Obstructive Pulmonary Disease [COPD] Treatment Market (Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
	◆商品コード：TMR23JN036 ◆発行会社（リサーチ会社）：Transparency Market Research ◆発行日：2022年10月31日 ◆ページ数：241 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥880,840	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,336,840	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,792,840	見積依頼/購入/質問フォーム

★Transparency Market Researchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の市場調査レポートでは、世界の慢性閉塞性肺疾患（COPD）治療薬市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬物クラス別（併用療法、気管支拡張薬、副腎皮質ステロイド、ホスホジエステラーゼ4型阻害剤、その他）分析、種類別（慢性気管支炎、肺気腫）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。また、企業情報として、F. Hoffmann-La Roche Ltd.、AstraZeneca、GlaxoSmithKline plc、Sanofi、Novartis AG、Teva Pharmaceutical Industries Ltd.、Mylan N.V.、Boehringer Ingelheim International GmbH、Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)、CHIESI Farmaceutici S.p.A.、Orion Corporation、Almirall、Theravance Biopharmaなどがあります。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の慢性閉塞性肺疾患（COPD）治療薬市場規模：薬物クラス別
- 併用療法の市場規模
- 気管支拡張薬の市場規模
- 副腎皮質ステロイドの市場規模
- ホスホジエステラーゼ4型阻害剤の市場規模
- その他慢性閉塞性肺疾患（COPD）治療薬の市場規模
・世界の慢性閉塞性肺疾患（COPD）治療薬市場規模：種類別
- 慢性気管支炎における市場規模
- 肺気腫における市場規模
・世界の慢性閉塞性肺疾患（COPD）治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の慢性閉塞性肺疾患（COPD）治療薬市場規模：地域別
- 北米の慢性閉塞性肺疾患（COPD）治療薬市場規模
- ヨーロッパの慢性閉塞性肺疾患（COPD）治療薬市場規模
- アジア太平洋の慢性閉塞性肺疾患（COPD）治療薬市場規模
- 中南米の慢性閉塞性肺疾患（COPD）治療薬市場規模
- 中東・アフリカの慢性閉塞性肺疾患（COPD）治療薬市場規模
・競争状況

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Scope of Report
TMR’s report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global chronic obstructive pulmonary disease (COPD) treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic obstructive pulmonary disease (COPD) treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the chronic obstructive pulmonary disease (COPD) treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global chronic obstructive pulmonary disease (COPD) treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease (COPD) treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global chronic obstructive pulmonary disease (COPD) treatment market.

The report delves into the competitive landscape of the global chronic obstructive pulmonary disease (COPD) treatment market. Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global chronic obstructive pulmonary disease (COPD) treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market chronic obstructive pulmonary disease (COPD) treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlight
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Reimbursement Scenario by Region/globally
5.3. Pipeline Analysis
5.4. Technological Advancements
5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
5.6. Disease Prevalence & Incidence Rate globally with key countries
5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Combination Therapy
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple therapy
6.3.1.4. Others
6.3.2. Bronchodilators
6.3.2.1. Long Acting Beta Agonist (LABA)
6.3.2.2. Short Acting Beta Agonist (SABA)
6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.3. Corticosteroids
6.3.4. Phosphodiesterase Type 4 Inhibitor
6.3.5. Mucokinetics
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Chronic Bronchitis
7.3.2. Emphysema
7.4. Market Attractiveness Analysis, by Type
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Combination Therapy
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple therapy
10.2.1.4. Others
10.2.2. Bronchodilators
10.2.2.1. Long Acting Beta Agonist (LABA)
10.2.2.2. Short Acting Beta Agonist (SABA)
10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.3. Corticosteroids
10.2.4. Phosphodiesterase Type 4 Inhibitor
10.2.5. Mucokinetics
10.2.6. Others
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Chronic Bronchitis
10.3.2. Emphysema
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Combination Therapy
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple therapy
11.2.1.4. Others
11.2.2. Bronchodilators
11.2.2.1. Long Acting Beta Agonist (LABA)
11.2.2.2. Short Acting Beta Agonist (SABA)
11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.3. Corticosteroids
11.2.4. Phosphodiesterase Type 4 Inhibitor
11.2.5. Mucokinetics
11.2.6. Others
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Chronic Bronchitis
11.3.2. Emphysema
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Combination Therapy
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple therapy
12.2.1.4. Others
12.2.2. Bronchodilators
12.2.2.1. Long Acting Beta Agonist (LABA)
12.2.2.2. Short Acting Beta Agonist (SABA)
12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.3. Corticosteroids
12.2.4. Phosphodiesterase Type 4 Inhibitor
12.2.5. Mucokinetics
12.2.6. Others
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Chronic Bronchitis
12.3.2. Emphysema
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Combination Therapy
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple therapy
13.2.1.4. Others
13.2.2. Bronchodilators
13.2.2.1. Long Acting Beta Agonist (LABA)
13.2.2.2. Short Acting Beta Agonist (SABA)
13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.3. Corticosteroids
13.2.4. Phosphodiesterase Type 4 Inhibitor
13.2.5. Mucokinetics
13.2.6. Others
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Chronic Bronchitis
13.3.2. Emphysema
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Combination Therapy
14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
14.2.1.3. Triple therapy
14.2.1.4. Others
14.2.2. Bronchodilators
14.2.2.1. Long Acting Beta Agonist (LABA)
14.2.2.2. Short Acting Beta Agonist (SABA)
14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
14.2.3. Corticosteroids
14.2.4. Phosphodiesterase Type 4 Inhibitor
14.2.5. Mucokinetics
14.2.6. Others
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Chronic Bronchitis
14.3.2. Emphysema
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Boehringer Ingelheim International GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. CHIESI Farmaceutici S.p.A.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Orion Corporation
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Almirall
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Theravance Biopharma
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Verona Pharmaceuticals
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Kyowa Hakko Kirin
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の慢性閉塞性肺疾患（COPD）治療薬市場2022年-2031年：薬物クラス別（併用療法、気管支拡張薬、副腎皮質ステロイド、ホスホジエステラーゼ4型阻害剤、去痰薬、その他）(Chronic Obstructive Pulmonary Disease [COPD] Treatment Market (Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の慢性閉塞性肺疾患（COPD）治療薬市場2022年-2031年：薬物クラス別（併用療法、気管支拡張薬、副腎皮質ステロイド、ホスホジエステラーゼ4型阻害剤、去痰薬、その他）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp